What is known and objective: Non-steroidal anti-inflammatory drugs (NSAIDs) have been commonly used to treat pain in sickle-cell disease (SCD), but NSAID use is associated with renal, gastrointestinal and cardiovascular toxicities. Our objective was to evaluate the use of aspirin and non-aspirin NSAIDs in SCD. 
| WHAT IS KNOWN AND OBJECTIVE
Sickle-cell disease (SCD) is a haemoglobin disorder characterized by mutations in the beta haemoglobin genes that affect 25 million people worldwide.
1,2 A combination of chronic, acute and neuropathic pain impairs the quality of life of patients with SCD. 3 Potential treatment options include opioids, non-steroidal anti-inflammatory drugs (NSAIDs) and acetaminophen. Since the discovery of aspirin at the end of 19th century and development of indomethacin and ibuprofen in the 1960s, 4 NSAIDs have been used in many conditions for their anti-inflammatory and analgesic properties by inhibiting cyclooxygenase (COX) enzymes and suppressing the production of prostaglandins. 5 Inflammation is a key component in the pathophysiology of SCD, and NSAIDs have been used to treat both vasoocclusive (VOC) pain episodes and chronic pain, 6 but NSAID use is associated with renal, cardiovascular and gastrointestinal (GI) toxicities. 7 The focus of this commentary is to evaluate the use of aspirin and non-aspirin NSAIDs as potential anti-inflammatory analgesic options in SCD.
| COMMENT

| Clinical efficacy
The evidence for using aspirin to treat VOC pain crisis is rather limited, although aspirin has been the mainstay of analgesics in patients with SCD in parts of Africa and the Middle East. [8] [9] [10] One small trial showed that parenteral aspirin could be a safe and effective approach in treating VOC in the paediatric patients with SCD. 10 Some studies reported that non-aspirin NSAIDs in combination with opioids in patients with SCD reduce pain, shorten the length of VOC episodes and decrease consumption of opioids, 11, 12 whereas other studies failed to show significant benefits. 13, 14 NSAIDs as a monotherapy were not effective as NSAIDs plus opioids in preventing 30-day emergency department (ED) revisits after treat-and-release ED visits for VOC. 15 According to the recommendations from National Heart, Lung, and Blood Institute (NHLBI), NSAIDs can be used as an adjuvant analgesic to treat mild to moderate pain during VOC, but the strength of the recommendation is moderate and the quality of evidence is low, and no references were provided to support the recommendations. 16 
| Potential toxicities
Despite the anti-inflammatory and analgesic benefits, the use of non- 27 Therefore, non-aspirin NSAID use in SCD is of concern because of the potential to cause or exacerbate kidney disease in this highrisk patient population. Consistent with these concerns, non-aspirin
NSAIDs were associated with a small but significant fall in eGFR and rise in urinary osmolality in patients with SCD compared to healthy controls [28] [29] [30] and the use of non-aspirin NSAIDs has also been associated with albuminuria and acute kidney injury in SCD cohorts. [31] [32] [33] The use of hydroxyurea has been shown to reduce albuminuria in patients with SCD, 34, 35 but there is no current evidence showing that the renal toxicities associated with non-aspirin NSAID use may be attenuated by hydroxyurea.
In addition to the renal toxicity, non-aspirin NSAIDs, especially COX-2 selective inhibitors, are known to cause cardiovascular toxicity. 36, 37 Ibuprofen, a commonly used over-the-counter NSAID, increased the risk of developing major coronary events 2.2-fold and NSAIDs in general doubled the risk of hospitalization due to heart failure. 37 The most recent Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen or Naproxen (PRECISION) trial showed that even the non-selective NSAIDs may not pose a lower cardiovascular risk compared to COX-2 selective NSAID. 38 It is recommended that non-aspirin NSAIDs should be avoided in patients at high risk of cardiovascular disease (CVD) 39 and may be only used for musculoskeletal pain as the last-line agents in patients with known CVD. 40 SCD is a hypercoagulable disease, and patients with SCD are at higher risk of developing ischaemic stroke, pulmonary hypertension and diastolic dysfunction. 41 Although there is no evidence showing that use of non-aspirin NSAIDs increases the CVD risk in the patients with SCD, in theory it poses additional risks in this patient population. Additionally, the GI toxicity associated with non-aspirin NSAID use, including dyspepsia, peptic ulcer disease and bleeding, is well documented in the general population, 42 as well as in SCD cohorts. high intake of non-aspirin NSAIDs was associated with a nine-fold increased risk of developing end-stage renal disease (ESRD), whereas no increased risk was observed in the frequent aspirin users. 46 Aspirin also has cardioprotective effects due to its antiplatelet function and it is widely used for secondary prevention of CVD, 54 although its utility in primary prevention of CVD, especially stroke, is still controversial due to the increased bleeding risk. 55 Stroke is one of the major complications in patients with SCD, 56 and the role of aspirin use in the treatment or prevention of stroke in SCD has not been established despite some efforts. 57 Additionally, decreased platelet aggregation induced by aspirin may ameliorate the frequency and severity of
VOCs. There are small trials studying aspirin use for VOC or stroke prevention in SCD patients with mixed results on these outcomes, but importantly no major side effects were reported. 57, 58 Similar to nonaspirin NSAIDs, use of aspirin may also cause upper and lower GI tract injuries, especially in patients with risk factors including a history of peptic ulcer or age >70 years.
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Despite its benefits in for preventing cardiovascular complications in conditions other than SCD, aspirin has several potential disadvantages compared to non-aspirin NSAIDs. First, the analgesic effect of aspirin appears to be weaker than non-aspirin NSAIDs. 60 The aspirin dose used for its cardioprotective effects is usually lower than the dose used for analgesic purposes although it is generally safe even among heavy users. [48] [49] [50] [51] Secondly, due to the association between aspirin and Reye's syndrome, it is recommended that aspirin not be used in children and adolescents with varicella or influenza-like symptoms.
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The incidence of Reye's syndrome is low, and withholding aspirin from children with viral illness symptoms should minimize the risk. 61 Thirdly, approximately one-third of strokes associated with SCD are haemorrhagic in nature, 56 and aspirin use may increase the risk of bleeding.
Therefore, the use of aspirin in SCD patients with pre-existing arteriovenous malformations such as moyamoya syndrome and intracranial aneurysm should be avoided.
The different side effect profile of non-aspirin NSAIDs and aspirin is related to the COX-1/COX-2 selectivity at their therapeutic doses. (PGI2), which is a vasodilator and inhibitor of platelet aggregation.
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The cardiovascular risk associated with non-aspirin NSAIDs is believed to result from COX-2-PGI2 inhibition. 64 The COX-2 selective
NSAIDs shift the balance of PGI2 and TxA2 in favour of TxA2-induced platelet activation and arterial vasoconstriction, posing a greater cardiovascular risk. The vasoconstriction caused by inhibition of COX-2 and subsequent prostaglandins is also responsible for renal toxicity. 7 Understanding the selectivity of the COX-1/COX-2 at the therapeutic doses and their pharmacokinetic/pharmacodynamic properties can guide the selection of appropriate NSAIDs.
Genetic variations, especially in cytochrome P450 (CYP) enzymes may lead to the interindividual difference in response to non-aspirin
NSAIDs. CYP2C9, a highly polymorphic enzyme, metabolizes several NSAIDs and has been implicated in intersubject variability in NSAID metabolic clearance. 65 The CYP2C9 polymorphism is common in patients with SCD and has been associated with different analgesic response to non-aspirin NSAIDs. 66, 67 In addition to genetic variation, the individual's clinical profile, particularly GI, renal and cardiovascular risk factors,
should be considered when selecting a NSAID and its appropriate dose.
Certain preventive approaches, such as co-administering proton pump inhibitors with either non-aspirin NSAIDs or aspirin, have been used to avoid GI side effects. 68, 69 In addition, researchers have been trying to develop novel agents which associate non-aspirin NSAIDs/aspirin with protective mediators to counteract the toxicities. Phosphatidylcholine was conjugated with NSAIDs to improve the GI safety, and chemical moieties that release protective mediators such as nitric oxide were structurally linked to NSAIDs to attenuate GI and cardiovascular toxicities, and this area of research has shown some promise. NSAIDs in pain management and stroke prevention in SCD is needed.
